Case report of two affected siblings in a family with thiamine metabolism dysfunction syndrome 5: a rare, but treatable neurodegenerative disease

• Published in: BMC neurology 2022-09, Vol.22 (1), p.1-373, Article 373
• Main Authors: Li, Xiaoyan, Huang, Zhixin, Chen, Yong, Sun, Xiaolan, Yi, Zhaoshi, Xie, Jihua, Yu, Xiongying, Chen, Hui, Zhong, Jianmin
• Format: Article
• Language: English
• Subjects: Ataxia; Case Report; Case studies; Consciousness; Degeneration; Dehydrogenases; Dietary supplements; Disease; Dosage and administration; Dyspnea; Encephalitis; Encephalopathy; Family; Gene mutations; Genetic aspects; Health aspects; Hydrogen bonds; Infections; Magnetic resonance imaging; Metabolic diseases; Metabolic disorders; Metabolism; Mitochondrial DNA; Mutation; Nervous system; Neurodegenerative diseases; Parents & parenting; Patients; Phenotypes; Proteins; Rare diseases; Risk factors; Siblings; Thiamine; Thiamine metabolism dysfunction syndrome 5; TPK1; Viral infections; Vitamin B; Vitamin B1
• ISSN: 1471-2377; 1471-2377
• DOI: 10.1186/s12883-022-02887-9

Background Thiamine metabolism dysfunction syndrome 5 (THMD5) is a rare inherited metabolic disorder due to thiamine pyrophosphokinase 1(TPK1) deficiency, caused by mutations in TPK1. The core symptoms of the disease is acute or subacute onset encephalopathy, ataxia, muscle hypotonia, and regression of developmental milestones in early infancy, repeatedly triggered by acute infectious illness. However, we report two brothers of THMD5 with compound heterozygous for the mutations c.614-1G > A,c.224 T > A p.(Ile75Asn), but the prognosis is quite different if thiamine suppled. According to our current knowledge, the missense variant c.224 T > A p.(Ile75Asn) was not published previously. Case presentation Here, we describe two affected siblings in a Chinese family, after an uneventful pregnancy to non-consanguineous and healthy parents. The older brother presented with normal development during the first 6 months of life, but developed regression of developmental milestones after, accompanied with muscle hypotonia, and chronic encephalopathy, and died at 1 year and 6 months old. The younger brother presented with acute onset encephalopathy, ataxia, muscle hypotonia, repeatedly triggered by acute infectious illness. He was compound heterozygous for the mutations c.614-1G > A,c.224 T > A p.(Ile75Asn) identified by whole exome sequencing. He was diagnosed of THMD5 when he was 11 month. Oral supplementation of thiamine 100 mg/day, the symptoms gradually disappeared. At the age of 2 years and 4 months, he stoped thiamine, his symptoms returned and were once again relieved by oral supplementation of thiamine 100 mg/day. Conclusions THMD5 is a rare, but treatable neurodegenerative disease, the clinical phenotype ranges from mild to severe. Massive-dose of thiamine supplementation may ameliorate the course of TPK1 deficiency. When similar clinical cases appear, gene detection is particularly important, which is conducive to early diagnosis. Treatment with thiamine while awaiting the outcome of diagnostic tests may be a good choice. Keywords: Thiamine metabolism dysfunction syndrome 5, TPK1, Thiamine, Case report